RuncheyResearch

Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive

Back to Forecasting

WVE Forecast Markets

Wave Life Sciences Ltd.

7
Active Markets
44%
Avg Probability
Price at Value
Apr 28, 2026

Our prediction ensemble suggests price is consistent with fundamentals.

7 markets analyzedConfidence: LOW
Read Full Thesis

All Markets

7 markets

Will WVE-007 Phase IIa 6-month data show total body weight loss of 5% or greater in the 240mg cohort?

Active
36%
Likely No
92% agreement
Jun 30, 2026
IG: 0.80

Will FDA indicate willingness to accept biomarker endpoints for WVE-006 accelerated approval by mid-2026?

Active
36%
Likely No
95% agreement
Sep 30, 2026
IG: 0.80

Will Wave Life Sciences maintain cash and equivalents above $400M at Q3 2026 quarter-end?

Active
59%
Likely Yes
96% agreement
Nov 15, 2026
IG: 0.64

Will GSK select a 5th program under the Wave Life Sciences collaboration by year-end 2026?

Active
60%
Likely Yes
94% agreement
Dec 31, 2026
IG: 0.64

Will Wave Life Sciences announce an equity offering or ATM program before key Q2 2026 clinical data readouts?

Active
24%
Likely No
94% agreement
Jun 30, 2026
IG: 0.64

Will Wave Life Sciences keep quarterly R&D expenses below $60M for all quarters of FY2026?

Active
35%
Likely No
92% agreement
Mar 15, 2027
IG: 0.48

Will Wave Life Sciences submit an NDA for WVE-N531 (DMD) to the FDA by year-end 2026?

Active
57%
Likely Yes
93% agreement
Dec 31, 2026
IG: 0.48

Resolution Timeline

Jun 30, 2026
Will WVE-007 Phase IIa 6-month data show total body weight loss of 5% or greater in the 240mg cohort?
Prediction: 36%
Jun 30, 2026
Will Wave Life Sciences announce an equity offering or ATM program before key Q2 2026 clinical data readouts?
Prediction: 24%
Sep 30, 2026
Will FDA indicate willingness to accept biomarker endpoints for WVE-006 accelerated approval by mid-2026?
Prediction: 36%
Nov 15, 2026
Will Wave Life Sciences maintain cash and equivalents above $400M at Q3 2026 quarter-end?
Prediction: 59%
Dec 31, 2026
Will GSK select a 5th program under the Wave Life Sciences collaboration by year-end 2026?
Prediction: 60%
Dec 31, 2026
Will Wave Life Sciences submit an NDA for WVE-N531 (DMD) to the FDA by year-end 2026?
Prediction: 57%
Mar 15, 2027
Will Wave Life Sciences keep quarterly R&D expenses below $60M for all quarters of FY2026?
Prediction: 35%